Free Newsletter
St. Jude lead punctures patients' hearts
Poor defibrillator patients. First they got jolted by Medtronic's Fidelis lead. Now, a St. Jude Medical connection wire is perforating their hearts. According to the medical journal PACE, four patients' hearts were punctured by the leads on their Riata defibrillators. Not surprisingly, St. Jude's stock fell 4 percent on the news.
St. Jude is striking back with stats about Riata's safety. The company has submitted its own article to PACE (Pacing and Clinical Electrophysiology), citing "new information" that the rate of performation problems is "below or at the low end" of what's been seen with other leads.
Some stock analysts called the story "old news." A study published in April had already showed that patients with the Riata product experienced significantly more perforations than those with Medtronic's product did. More data needed? Sounds like it.
- see this release from St. Jude
- read the report from the Houston Chronicle
- read about St. Jude's response at TwinCities.com
Related Articles:
St. Jude gets OK for radio-frequency heart implants. Report
Medtronic withdraws defibrillator part. Report
Medtronic sued over faulty defibrillator parts. Report
Patients face defibrillator recalls. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: